One of Cincinnati's largest marketing firms has inked a deal to buy a Dallas-based peer — its second acquisition in as many months — as part of its continued aggressive growth strategy.
Union Township-based Relevate Health, a health care marketing agency for pharmaceutical, biotech and medical device brands, has acquired ConneXion360, a Dallas-based health care broadcasting network, the companies said Monday.
Terms were not disclosed. The deal is Relevate Health’s second transaction of 2022 — the company bought Boston-based Axon Communications in February — and its third since taking on funding from Denver-based private equity firm Mountaingate Capital in late 2020.
For Relevate, adding ConneXion360 further expands its offerings, CEO Jeff Spanbauer said. ConneXion360’s network allows biopharma marketers to deliver their brand messages to a target list of health care providers within hospitals, clinics and private practices.
Those solutions complement Relevate Health’s suite of services, which solves the last-mile challenge many brands face in connecting their campaign to target audiences.
“Quite simply, it means more access to HCPs (health care providers) by reps, MSLs (medical science liaisons) and KAMs (key account managers),” Spanbauer said in a release.
ConneXion360, founded in 2008, offers one-on-one engagement, key account messaging, video and national broadcast capabilities.
As part of the acquisition, George Griffith, ConneXion360’s CEO and co-founder, joins Relevate as executive VP of omnichannel solutions. Relevate will maintain the office in Dallas.
ConneXion360 will also transition a staff of 50, bringing Relevate’s employee count to more than 200.
Relevate, which is headquartered in Union Township with additional offices in New Jersey and Boston, and now Dallas, is the region’s fifth-largest advertising and marketing firm, per Courier research.
The company serves more than 185 brands from 90 pharmaceutical, biotech and medical device manufacturers, as well as 24 hospital systems. Its partners include Pfizer, Astellas, Genentech, Eli Lilly and AstraZeneca.
